AYOXXA to develop multiplex immunoassay to support treatment of sepsis patients

AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company’s innovative bead-based protein analysis platform LUNARIS™.

As a result of the research project, the multiplex assay will be available as a commercial detection kit. It will be marketed initially for use in academic and preclinical research and, after further validation, for routine use in the clinic in the medium term.

The project is funded by the "European Regional Development Fund" (ERDF) and comprises a consortium of North Rhine-Westphalian companies, university hospitals and universities. Head of the project is Prof. Michael Adamzik from the Ruhr University Bochum and the University Hospital Bochum, Department of Anesthesiology, Intensive Care and Pain Therapy. The duration of the project is set for three years.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare